Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prospects of Neutralizing Nanobodies Against SARS-CoV-2
Fangfang Chen, Zhihong Liu, Fan Jiang
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19
Jiandong Huo, Halina Mikolajek, Audrey Le Bas, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 132
Nanobodies: Robust miniprotein binders in biomedicine
Jeffrey Yong Joon Kim, Zhe Sang, Yufei Xiang, et al.
Advanced Drug Delivery Reviews (2023) Vol. 195, pp. 114726-114726
Open Access | Times Cited: 44
Advances in Nanomaterial-Based Platforms to Combat COVID-19: Diagnostics, Preventions, Therapeutics, and Vaccine Developments
Niaz Mahmud, Muzahidul I. Anik, M. Khalid Hossain, et al.
ACS Applied Bio Materials (2022) Vol. 5, Iss. 6, pp. 2431-2460
Closed Access | Times Cited: 46
Covalently Engineered Protein Minibinders with Enhanced Neutralization Efficacy against Escaping SARS-CoV-2 Variants
Yu Han, Zhenlin Yang, Hengrui Hu, et al.
Journal of the American Chemical Society (2022) Vol. 144, Iss. 13, pp. 5702-5707
Closed Access | Times Cited: 36
Single domain antibody: Development and application in biotechnology and biopharma
Ting Yu, Fang Zheng, Wenbo He, et al.
Immunological Reviews (2024)
Open Access | Times Cited: 8
Screening and optimization of shark nanobodies against SARS-CoV-2 spike RBD
Xiaochun Liu, Yanqing Wang, Li-shan Sun, et al.
Antiviral Research (2024) Vol. 226, pp. 105898-105898
Closed Access | Times Cited: 6
Promising Diagnostic and Therapeutic Approaches Based on VHHs for Cancer Management
Ying Cong, Nick Devoogdt, Philippe Lambin, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 371-371
Open Access | Times Cited: 5
Single Domain Antibody application in bacterial infection diagnosis and neutralization
Qian Qin, Hao Liu, Wenbo He, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 21
Multi-omics for COVID-19: driving development of therapeutics and vaccines
Mengyu Guo, Muya Xiong, Jinying Peng, et al.
National Science Review (2023) Vol. 10, Iss. 9
Open Access | Times Cited: 12
Highly potent and broadly neutralizing anti-CD4 trimeric nanobodies inhibit HIV-1 infection by inducing CD4 conformational alteration
Linjing Zhu, Bilian Huang, Xiangyao Wang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
A Class of Shark‐Derived Single‐Domain Antibodies can Broadly Neutralize SARS‐Related Coronaviruses and the Structural Basis of Neutralization and Omicron Escape
Bo Feng, Zhilong Chen, Jing Sun, et al.
Small Methods (2022) Vol. 6, Iss. 7
Open Access | Times Cited: 19
High-throughput strategies for monoclonal antibody screening: advances and challenges
Xiaodong Wang, Bangzheng Ma, Soak Kuan Lai, et al.
Journal of Biological Engineering (2025) Vol. 19, Iss. 1
Open Access
Development and Characterization of a Novel NEIL1 Nanobody
Marlo K. Thompson, Mark H. Eggers, Deolinda Flores, et al.
DNA repair (2025), pp. 103849-103849
Closed Access
Structural and Computational Studies of the SARS-CoV-2 Spike Protein Binding Mechanisms with Nanobodies: From Structure and Dynamics to Avidity-Driven Nanobody Engineering
Gennady M. Verkhivker
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 6, pp. 2928-2928
Open Access | Times Cited: 16
VHH Structural Modelling Approaches: A Critical Review
Poonam Vishwakarma, Akhila Melarkode Vattekatte, Nicolas K. Shinada, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3721-3721
Open Access | Times Cited: 15
Physicochemical effects of emerging exchanges on the spike protein's RBM of the SARS-CoV-2 Omicron subvariants BA.1-BA.5 and its influence on the biological properties and attributes developed by these subvariants
Robério Amorim de Almeida Pondé
Virology (2023) Vol. 587, pp. 109850-109850
Closed Access | Times Cited: 9
Structure-guided design of a trivalent nanobody cluster targeting SARS-CoV-2 spike protein
Xinyi Jiang, Qin Qin, Haixia Zhu, et al.
International Journal of Biological Macromolecules (2023) Vol. 256, pp. 128191-128191
Closed Access | Times Cited: 9
COVID‐19 cooling: Nanostrategies targeting cytokine storm for controlling severe and critical symptoms
Yu Zheng, Yuke Li, Li Mao, et al.
Medicinal Research Reviews (2023) Vol. 44, Iss. 2, pp. 738-811
Closed Access | Times Cited: 9
Single-domain antibodies against SARS-CoV-2 RBD from a two-stage phage screening of universal and focused synthetic libraries
Fangfang Chen, Zhihong Liu, Wei Kang, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Nanobodies: from high-throughput identification to therapeutic development
Peter C. Fridy, Michael P. Rout, Natalia E. Ketaren
Molecular & Cellular Proteomics (2024), pp. 100865-100865
Open Access | Times Cited: 3
Nanobody assemblies with fully flexible topology enabled by genetically encoded tetrazine amino acids
Elise M. Van Fossen, Riley M. Bednar, Subhashis Jana, et al.
Science Advances (2022) Vol. 8, Iss. 18
Open Access | Times Cited: 13
Nanobodies: COVID-19 and Future Perspectives
G Valenzuela, Zaray Miranda-Chacón, Constanza Salinas-Rebolledo, et al.
Frontiers in Drug Discovery (2022) Vol. 2
Open Access | Times Cited: 13
Evaluation of SARS-CoV-2-Neutralizing Nanobody Using Virus Receptor Binding Domain-Administered Model Mice
Song Liu, Guanghui Li, Lei Ding, et al.
Research (2022) Vol. 2022
Open Access | Times Cited: 12
Engineered Multivalent Nanobodies Efficiently Neutralize SARS-CoV-2 Omicron Subvariants BA.1, BA.4/5, XBB.1 and BQ.1.1
Jiali Wang, Bingjie Shi, Hanyi Chen, et al.
Vaccines (2024) Vol. 12, Iss. 4, pp. 417-417
Open Access | Times Cited: 2
Next generation single-domain antibodies against respiratory zoonotic RNA viruses
Iris C. Swart, W. van Gelder, Cornelis A. M. de Haan, et al.
Frontiers in Molecular Biosciences (2024) Vol. 11
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top